374
Views
16
CrossRef citations to date
0
Altmetric
Articles

Synthesis, crystal structure and anticancer activity of the dibutyltin(IV)oxide complexes containing substituted salicylaldehyde-o-aminophenol Schiff base with appended donor functionality

, , , , , & show all
Pages 486-494 | Received 10 Dec 2017, Accepted 02 Jan 2019, Published online: 22 Feb 2019
 

Abstract

Schiff base butyltin complexes C1C3 have been synthesized via the reaction of dibutyltin oxide with the substituted salicylaldehyde-o-aminophenol Schiff base ligands (L1L3), respectively. The complexes have been characterized by elemental analysis, IR, UV-Vis, 1H NMR, 13C NMR spectra and the crystal structures have been determined by X-ray diffraction. The anticancer activity of the Schiff base ligands L1L3 and complexes C1C3 against five species of cancer cells which are MCF7, Colo205, NCI-H460, Hela and HepG2 were tested respectively, the tests showed that C3 exhibited significant anticancer activity for the cancer cells in comparison with other complexes. The interaction between C3 and calf thymus DNA were studied by fluorescence, UV-Vis and Viscosity experiment, the results show that the interaction of C3 with calf thymus DNA was intercalation.

Additional information

Funding

This work was supported by the Hunan Provincial Natural Science Foundation of China (Nos. 2017JJ3003, 2016JJ5004) and Foundation of Key Laboratory of Functional Metal-Organic Compounds of Hunan Province (No. MO18K01).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.